Domine Gomez, Manuel manuel.domine@uam.es
Actividades
- Artículos 38
- Libros 1
- Capítulos de libro 0
- Congresos 0
- Documentos de trabajo 0
- Informes técnicos 0
- Proyectos de investigación 0
- Tesis dirigidas 0
- Patentes o licencias de software 0
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase II IMPULSE study
- Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M, Kollmeier J, Sadjadian P, Fröhling KP, Huber RM, Wolf M, IMPULSE study team
Annals Of Oncology (p. 2076-2084) - 1/10/2018
10.1093/annonc/mdy326 Ver en origen
- ISSN 09237534
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
- de la Rosa, CA
- Castellanos, PC
- Lazaro-Quintela, M
- Domine, M
- Estevez, SV
- Lopez-Vivanco, G
- Perez, JLF
- Romero, JLA
- Delgado, LF
- Giron, CG
- Tain, PD
- Alvarez, RA
- Sanchis, PM
- Canton, IF
- Abos, IM
- Aguillo, MM
- Gutierrez, LGA
- Granados, ALO
- Cabellos, RA
- Sebastian, AG
- Sifuentes, LFG
- Reguart, N
Lung Cancer (p. 83-93) - 1/11/2022
10.1016/j.lungcan.2022.09.010 Ver en origen
- ISSN 01695002
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
- Majem, M
- Goldman, JW
- John, T
- Grohe, C
- Laktionov, K
- Kim, SW
- Kato, T
- Vu, HV
- Lu, S
- Li, SQ
- Lee, KY
- Akewanlop, C
- Yu, CJ
- de Marinis, F
- Bonanno, L
- Domine, M
- Shepherd, FA
- Atagi, S
- Zeng, LM
- Kulkarni, D
- Medic, N
- Tsuboi, M
- Herbst, RS
- Wu, YL
Clinical Cancer Research (p. 2286-2296) - 1/6/2022
10.1158/1078-0432.ccr-21-3530 Ver en origen
- ISSN 15573265
Galectin-1, a novel promising target for outcome prediction and treatment in SCLC
- Corral JM
- Puerto-Nevado LD
- Cedeño M
- Río-Vilariño A
- Mahillo-Fernández I
- Galeano C
- Baños N
- García-Foncillas J
- Dómine M
- Cebrián A
Biomedicine & Pharmacotherapy (p. 113987-113987) - 1/12/2022
- ISSN 07533322
- iMarina
First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
- Provencio-pulla, M
- Ortega, AL
- Coves, J
- Franco, F
- Marse, R
- Domine, M
- Guirado, M
- Carcereny, E
- Fernandez, N
- Martinez, E
- Blanco, R
- Leon, L
- Sanchez, JM
- Sullivan, I
- Cobo, M
- Sanchez, A
- Massuti, B
Journal Of Thoracic Oncology (p. S123-S124) - 1/9/2022
- ISSN 15560864
- iMarina
Extensive pleural effusion as first manifestation of wall rhabdomyosarcoma
- Casal Rubio J
- Domine Gomez M
- Lopez Sacconi F
- Jerves Andrade M
- Vicente J
Oncologia (p. 403-408) - 1/1/1988
- ISSN 03784835
- iMarina
Erratum to: Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary
- Provencio Pulla, Mariano
- Sánchez, A
- Artal Cortés, Ángel
- Sánchez Torres, José Miguel
- Castro Carpeño, Javier de
- Dómine Gómez, Manuel
- Viñolas Segarra, Núria
- Sánchez Ruiz, A
- Pérez, Francisco Javier
Clinical & Translational Oncology (p. 670-670) - 1/8/2013
10.1007/s12094-013-1050-0 Ver en origen
- ISSN 1699048X
- iMarina
- iMarina
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
- J Corral
- Margarita Majem
- Delvys Rodríguez Abreu
- Enric Carcereny Costa
- Ángel Artal Cortés
- M Llorente
- José María López-Picazo González
- Yolanda García García
- Manuel Dómine Gómez
- M P López Criado
Clinical & Translational Oncology (p. 1270-1279) - 1/1/2019
- ISSN 1699048X
- iMarina
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüro?lu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Ka?arnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators
Lancet Oncology (p. 51-65) - 1/1/2021
10.1016/s1470-2045(20)30539-8 Ver en origen
- ISSN 14702045
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
- Provencio M
- Cobo M
- Rodriguez-Abreu D
- Calvo V
- Carcereny E
- Cantero A
- Bernabé R
- Benitez G
- Castro RL
- Massutí B
- del Barco E
- García Campelo R
- Guirado M
- Camps C
- Ortega AL
- González Larriba JL
- Sánchez A
- Casal J
- Sala MA
- Juan-Vidal O
- Bosch-Barrera J
- Oramas J
- Dómine M
- Trigo JM
- Blanco R
- Calzas J
- Morilla I
- Padilla A
- Pimentao J
- Sousa PA
- Torrente M
Bmc Cancer - 1/12/2022
10.1186/s12885-022-09830-8 Ver en origen
- ISSN 14712407
Este/a investigador/a no tiene capítulos de libro.
Este/a investigador/a no tiene congresos.
Este/a investigador/a no tiene documentos de trabajo.
Este/a investigador/a no tiene informes técnicos.
Este/a investigador/a no tiene proyectos de investigación.
Este/a investigador/a no tiene tesis dirigidas.
Este/a investigador/a no tiene patentes o licencias de software.
Perfiles de investigador/a
-
ORCID
-
Scopus Author ID
-
Dialnet id